secwatch / observer
BBOT BridgeBio Oncology Therapeutics, Inc.
CIK 0001869105 17 ready 8-Ks latest May 12, 2026, 5:07 PM ET RSS · JSON
Activity: NORMAL 1 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (5)
Ready 8-Ks 17
Latest filing June 22, 2026, 4:05 PM ET
Top materiality 0.90
Event mix m_and_a ×6 · other_material ×4 · leadership ×4
Sentiment 7 pos · 0 neg · 10 neu
Latest earnings reported 2026-Q1
Executive change recent →

Recent 8-K filings for BBOT

Highest-materiality recent filing

BridgeBio Oncology closes SPAC merger; raises $260.9M PIPE, $381.8M total gross proceeds

August 13, 2025, 7:59 PM ET M&A materiality 0.90 positive item 1.01item 2.01item 3.02item 9.01item 4.01item 3.03item 5.03item 8.01item 5.01item 5.02item 5.05item 5.06item 7.01 ◈ Governance Changes ×4◈ M&A Transactions

Read filing →

Executive changes

Departed

Michelle Doig

Class I director
BBOT · BridgeBio Oncology Therapeutics, Inc.
Effective
2026-06-16
Filed
June 22, 2026, 4:05 PM ET
On June 16, 2026, Michelle Doig notified BridgeBio Oncology Therapeutics, Inc. (the “Company”), of her resignation as a member of the Board of Directors of the Company (the “Board”) upon the completion of her term as a Class I director, effective as of June 16, 2026, the date of the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”).
Appointed

Pedro J. Beltran

Member of the Board of Directors
BBOT · BridgeBio Oncology Therapeutics, Inc.
Effective
2026-04-20
Filed
April 29, 2026, 7:59 PM ET
Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.
Departed

Eli Wallace

President and Chief Executive Officer
BBOT · BridgeBio Oncology Therapeutics, Inc.
Effective
2026-04-20
Successor
Pedro J. Beltran
Filed
April 29, 2026, 7:59 PM ET
Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.
Appointed

Pedro J. Beltran

President and Chief Executive Officer
BBOT · BridgeBio Oncology Therapeutics, Inc.
Effective
2026-04-20
Filed
April 29, 2026, 7:59 PM ET
Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.
Departed

Eli Wallace

Member of the Board of Directors
BBOT · BridgeBio Oncology Therapeutics, Inc.
Effective
2026-04-20
Successor
Pedro J. Beltran
Filed
April 29, 2026, 7:59 PM ET
Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.
Appointed

John Schmid

Director
BBOT · BridgeBio Oncology Therapeutics, Inc.
Effective
2024-02-08
Filed
February 14, 2024, 6:59 PM ET
Mr. Mark C. McKenna and Mr. John Schmid (the “ Directors ”) were appointed to the board of directors of the Company
Appointed

Mark C. McKenna

Director
BBOT · BridgeBio Oncology Therapeutics, Inc.
Effective
2024-02-08
Filed
February 14, 2024, 6:59 PM ET
Mr. Mark C. McKenna and Mr. John Schmid (the “ Directors ”) were appointed to the board of directors of the Company

Earnings & guidance

2026-Q1 EPS reported -$526.11 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event m_and_a

7 positive 0 negative 10 neutral

source · BBOT on sec.gov